Physiomics plc (LSE:PYC) has secured a new agreement with Numab Therapeutics to provide pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation services for a First-In-Human clinical study within Numab’s inflammation pipeline. This partnership marks an important expansion for Physiomics, extending its Model-Informed Drug Development expertise beyond oncology into inflammatory diseases. The project is set to start shortly and is expected to complete within six months, reinforcing Physiomics’ commitment to supporting early-stage drug development decisions.

Despite this strategic collaboration, Physiomics continues to face financial headwinds, including falling revenues and ongoing losses. Technical analysis signals a bearish market outlook. While the new contract highlights growth potential, significant valuation challenges and financial instability remain key concerns for investors.

About Physiomics plc

Physiomics specializes in advanced mathematical modelling, biostatistics, and data science to accelerate the development of novel therapeutics and personalized medicine. With a track record of supporting over 100 commercial projects, the company partners with leading biopharma firms—including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and Cancer Research UK—to optimize drug development strategies through sophisticated simulation and analysis.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.